Bolagets tillgång till kritiska råvaror borgar för snabbare utveckling inom deras två gruvprojekt.
While we believe performance was solid in Q1, we expect revenue growth faces a tough comparison as Q...
Elanders will present its Q1 report on 21 April. We expect a somewhat muted quarter with a 13% y/y E...
Strategisk översyn Beijer Alma meddelade i samband med Q4-rapporten en översyn av ägandet i Habia Ca...
Redeye retains its positive view of Speqta, following a revised Investment Case due to Speqta’s dive...
Cline Scientific AB (”Cline” eller ”Bolaget”) tillkännagav den 12:e april att bolaget framgångsrikt ...
Novartis presented new data from its CANOPY-1 trial at the AARC annual meeting yesterday.
Yesterday, the AGM approved the BoD’s dividend proposal and decided on a share split with a ratio of...
En era tar slut... BTS grundare och huvudägare Henrik Ekelund har meddelat att han efter 36 år komm...
Redeye comments on the outcome of the completed rights issue and adjusts its fair value range accord...
Redeye updates its estimates prior to the Q1 report, following the divestments in Corporate Finance ...
Redeye initiates coverage of Fram Skandinavien, a Vietnam-based combination of investment company an...
NoHo released strong March sales figures with around EUR 26m sales (guided to be over EUR 23m), up 2...
Investmentbolaget Archelon investerar i framför allt i prospekteringsbolag i gruvnäringen, men även ...
Redeye comments on the letter of interest with Concord Medical in China.
Redeye gives a comment on today’s March ARR update from Hoylu, closing the first quarter in 2022.
Förvärvet av Corepart stängt och de ligger nu i årstakt på 450 mkr i omsättning Nordic LEVEL Group h...
En svag avslutning på fjolåret Under Q4'21 rapporterade Ayima totala intäkter om 43,4 mkr (Q4’20: 47...
Cibus announced on 11 April that the board of directors has decided to withdraw its proposal to issu...
I torsdags förra veckan (7 april 2022) meddelade Medclair Invest om att det helägda dotterbolaget Me...
